异常凝血酶原和肝细胞癌  

Des-gamma-carboxy-prothrombin and Hepatocellular carcinoma

作　　者：袁联文[1] 唐伟[1] 幕内.雅敏[1] 

机构地区：[1]东京大学医学部附属病院肝胆胰外科

出　　处：《肿瘤防治杂志》2002年第5期544-546,共3页China Journal of Cancer Prevention and Treatment

摘　　要：目前肝细胞癌 (hepatocellularcarcinoma ,HCC)的诊断主要有影像学诊断和血清肿瘤标志物的检测。异常凝血酶原 (des gamma carboxy prothrombin ,DCP)又被称为PIVKA II (proteininducedbyvita minKabsenceorantagonist II) ,与AFP(alpha fetoprotein)和AFP L3(alpha fetoproteinL3fraction)一样被认为是一种很有价值的肝细胞癌血清肿瘤标志物。在HCC的检测诊断上 ,它们之间无明显相关关系 ,而表现为一定的互补性 ,结合影像学诊断 ,动态观测HCC高危 (肝炎、肝硬化 )人群 ,这些血清肿瘤标志物有助于HCC的早期发现 ,同时对HCC的手术疗效的评价。The mainstay for the diagnosis for hepatocellular carcinoma (HCC) includes imaging modalities and serological tumor markers.Des-gamma-carboxy-prothrombin (DCP,also known as PIVKA-II:Protein induced by vitamin K absence or antagonist-II),as well as alpha-fetoprotein (AFP) and alpha-fetoprotein L3 fraction (AFP-L3),has been considered as a useful serological tumor marker for HCC.There is not a correlation with these serological tumor markers,but they make up a whole each other in the diagnosis of HCC.Following serological tumor markers in high-risk patients with chronic hepatitis or liver cirrhosis,combining with imaging,can signal the development of HCC in the early stage and make accurate evaluation of the efficacy of therapies for HCC as possible.Moreover,these tumor markers can be used as the biological indicators for malignancy and the prediction of the outcome.

关 键 词：异常凝血酶原 肝细胞癌 肿瘤标志物 

分 类 号：R735.7[医药卫生—肿瘤]